Short Interest in Bionomics Limited (NASDAQ:BNOX) Rises By 690.0%

Bionomics Limited (NASDAQ:BNOX – Get Rating) was the recipient of a large growth in short interest in May. As of May 15th, there was short interest totalling 7,900 shares, a growth of 690.0% from the April 30th total of 1,000 shares. Based on an average trading volume of 136,400 shares, the days-to-cover ratio is presently 0.1 days.

Analyst Upgrades and Downgrades

Several research firms have weighed in on BNOX. Evercore ISI upgraded shares of Bionomics from an “in-line” rating to an “outperform” rating and set a $6.00 price objective for the company in a research report on Friday, March 10th. Cantor Fitzgerald reduced their target price on shares of Bionomics from $10.00 to $8.00 in a research note on Friday, March 10th. Loop Capital raised their target price on shares of Bionomics from $10.00 to $17.00 and gave the company a “buy” rating in a research note on Thursday, March 9th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Bionomics in a research note on Thursday, March 9th.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bionomics stock. Point72 Asset Management L.P. acquired a new position in shares of Bionomics Limited (NASDAQ:BNOX – Get Rating) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 128,000 shares of the company’s stock, valued at approximately $595,000. Point72 Asset Management L.P. owned about 1.57% of Bionomics at the end of the most recent reporting period. Institutional investors own 2.73% of the company’s stock.

Bionomics Price Performance

Bionomics stock opened at $2.31 on Friday. The company’s 50 day simple moving average is $2.33 and its 200 day simple moving average is $4.12. Bionomics has a fifty-two week low of $1.80 and a fifty-two week high of $10.90.

About Bionomics

(Get Rating)

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.